P-135 Mucosal Disease Activity May Predict Therapeutic Response to Fecal Microbiome Transplantation in Pediatric Ulcerative Colitis

2014 ◽  
Vol 20 ◽  
pp. S82-S83
Author(s):  
Nagy-Szakal Dorottya ◽  
Ihekweazu Faith ◽  
Hemarajata Peera ◽  
Haynes Abria ◽  
Schady Deborah ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Therapeutic Response ◽  
Fecal Microbiome ◽  
Mucosal Disease

scholarly journals Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study

Gut ◽  
2019 ◽  
Vol 69 (9) ◽  
pp. 1629-1636 ◽  
Author(s):  
Christian Maaser ◽  
Frauke Petersen ◽  
Ulf Helwig ◽  
Imma Fischer ◽  
Alexander Roessler ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Sigmoid Colon ◽  
Therapeutic Response ◽  
Bowel Wall ◽  
Activity Index ◽  
Point Of Care ◽  
Clinical Relapse ◽  
Short Term Treatment ◽  
Descending Colon

ObjectiveProspective evaluation of intestinal ultrasound (IUS) for disease monitoring of patients with ulcerative colitis (UC) in routine medical practice.DesignTRansabdominal Ultrasonography of the bowel in Subjects with IBD To monitor disease activity with UC (TRUST&UC) was a prospective, observational study at 42 German inflammatory bowel disease-specialised centres representing different care levels. Patients with a diagnosis of a proctosigmoiditis, left-sided colitis or pancolitis currently in clinical relapse (defined as Short Clinical Colitis Activity Index ≥5) were enrolled consecutively. Disease activity and vascularisation within the affected bowel wall areas were assessed by duplex/Colour Doppler ultrasonography.ResultsAt baseline, 88.5% (n=224) of the patients had an increased bowel wall thickness (BWT) in the descending or sigmoid colon. Even within the first 2 weeks of the study, the percentage of patients with an increased BWT in the sigmoid or descending colon decreased significantly (sigmoid colon 89.3%–38.6%; descending colon 83.0%–42.9%; p<0.001 each) and remained low at week 6 and 12 (sigmoid colon 35.4% and 32.0%; descending colon 43.4% and 37.6%; p<0.001 each). Normalisation of BWT and clinical response after 12 weeks of treatment showed a high correlation (90.5% of patients with normalised BWT had symptomatic response vs 9.5% without symptomatic response; p<0.001).ConclusionsIUS may be preferred in general practice in a point-of-care setting for monitoring the disease course and for assessing short-term treatment response. Our findings give rise to the assumption that monitoring BWT alone has the potential to predict the therapeutic response, which has to be verified in future studies.

Tu1784 – Abnormalities in the Fecal Microbiome of Patients with Ulcerative Colitis Based on Lenght of Diagnosis and Disease Activity

2019 ◽  
Vol 156 (6) ◽  
pp. S-1122
Author(s):  
Patricio Ibañez ◽  
Suzanne Devkota ◽  
rodrigo quera ◽  
Daniela Simian ◽  
Mauricio Moreno ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Fecal Microbiome

Corticosteroid use impacts Mucosal Disease Activity in African Americans with Ulcerative Colitis

2009 ◽  
Vol 15 ◽  
pp. S25
Author(s):  
T Malik ◽  
R Oster ◽  
A Eckhoff ◽  
S Peter ◽  
A Gutierrez
Keyword(s):  
Ulcerative Colitis ◽  
African Americans ◽  
Disease Activity ◽  
Mucosal Disease

scholarly journals Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response

Medicine ◽  
2019 ◽  
Vol 98 (21) ◽  
pp. e15748 ◽  
Author(s):  
Wei-Chen Lin ◽  
Chen-Wang Chang ◽  
Ming-Jen Chen ◽  
Tzu-Chi Hsu ◽  
Horng-Yuan Wang
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Therapeutic Response

P113 STUDY OF THE PROTEOMIC PROFILE IN PATIENTS WITH ULCERATIVE COLITIS, ITS CORRELATION WITH DIAGNOSIS AND DISEASE ACTIVITY

2018 ◽  
Vol 154 (1) ◽  
pp. S58
Author(s):  
Salah Badr El-Din ◽  
Ezzat Ali ◽  
Doaa Header ◽  
Pacint Moez ◽  
Mohamed Ibrahim
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Proteomic Profile

Disease activity, pANCA and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis

2009 ◽  
Vol 47 (09) ◽  
Author(s):  
M Jürgens ◽  
R Laubender ◽  
F Hartl ◽  
M Weidinger ◽  
J Wagner ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Early Response

scholarly journals Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lena Öhman ◽  
Anders Lasson ◽  
Anna Strömbeck ◽  
Stefan Isaksson ◽  
Marcus Hesselmar ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Gut Microbiota ◽  
Disease Activity ◽  
Temporal Dynamics ◽  
Fecal Microbiota ◽  
Disease Stage ◽  
Dietary Interventions ◽  
Microbial Composition ◽  
Fecal Samples ◽  
Specific Species

AbstractPatients with ulcerative colitis (UC) have an altered gut microbiota composition, but the microbial relationship to disease activity needs to be further elucidated. Therefore, temporal dynamics of the fecal microbial community during remission and flare was determined. Fecal samples were collected at 2–6 time-points from UC patients during established disease (cohort EST) and at diagnosis (cohort NEW). Sampling range for cohort EST was 3–10 months and for cohort NEW 36 months. Relapses were monitored for an additional three years for cohort EST. Microbial composition was assessed by Genetic Analysis GA-map Dysbiosis Test, targeting ≥ 300 bacteria. Eighteen patients in cohort EST (8 with maintained remission and 10 experiencing a flare), provided 71 fecal samples. In cohort NEW, 13 patients provided 49 fecal samples. The microbial composition showed no clustering related to disease activity in any cohort. Microbial dissimilarity was higher between than within patients for both cohorts, irrespective of presence of a flare. Microbial stability within patients was constant over time with no major shift in overall composition nor modification in the abundance of any specific species. Microbial composition was not affected by intensified medical treatment or linked to future disease course. Thus in UC, the gut microbiota is highly stable irrespective of disease stage, disease activity or treatment escalation. This suggests that prolonged dietary interventions or repeated fecal transplantations are needed to be able to induce permanent alterations of the gut microbiota.

scholarly journals Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jiao Sun ◽  
Yameng Sui ◽  
Yunqing Wang ◽  
Lijun Song ◽  
Dong Li ◽  
...  
Keyword(s):  
T Cell ◽  
Disease Activity ◽  
Therapeutic Effect ◽  
Mean Fluorescence Intensity ◽  
Therapeutic Response ◽  
Severe Disease ◽  
T Cell Subsets ◽  
Poor Responders ◽  
Lower Plasma ◽  
Immunological Parameters

AbstractGalectin-9 (Gal-9) is a multifunctional immunomodulatory factor highly expressed in RA. This study aimed to investigate the expression of Gal-9 and its correlation with disease activity and therapeutic response in RA patients. Active RA patients were enrolled and treated with tacrolimus (TAC) alone or in combination therapy for 12 weeks in a prospective cohort study. Clinical and immunological parameters were recorded at baseline and week 12. We measured Gal-9 expression in different T cell subsets and in plasma. The disease activity of RA patients decreased after treatment. At baseline, the Gal-9 expression percentage was higher in the group with severe disease than in mild or moderate groups. After treatment, the Gal-9 expression in CD3+, CD4+, CD8+ and CD4-CD8− cell subsets decreased, as well as Gal-9 mean fluorescence intensity in CD3+, CD4+ and CD8+ T cells. Similarly, plasma Gal-9 levels were lower at week 12 than at baseline. Good responders showed significantly lower Gal-9 expression on CD3+ and CD4+ T cell subsets and lower plasma Gal-9 levels than poor responders. Gal-9 expression positively correlates with disease activity in RA patients. Gal-9 can be regarded as a new biomarker for evaluating RA activity and therapeutic effect, including TAC.

Sign in / Sign up

Export Citation Format

Share Document